Bleeding and thrombosis associated with ventricular assist device therapy

Journal of Heart and Lung Transplantation

Volumn 36, Issue 11, 2017, Pages 1164-1173

  Shah, Palak ^a   Tantry, Udaya S ^a   Bliden, Kevin P ^a   Gurbel, Paul A ^a  

^a INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

anti thrombotic therapy; gastrointestinal bleeding; hemolysis; left ventricular assisted device; thrombosis

Indexed keywords

BIOLOGICAL MARKER; DABIGATRAN; DALTEPARIN; ENOXAPARIN; VON WILLEBRAND FACTOR;

ACQUIRED VON WILLEBRAND DISEASE TYPE2A; ANGIODYSPLASIA; ANGIOGENESIS; ARTICLE; BLEEDING; BLOOD CLOTTING; FLOW KINETICS; GASTROINTESTINAL HEMORRHAGE; HEMOLYSIS; HUMAN; POSTOPERATIVE HEMORRHAGE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK FACTOR; SYSTOLIC HEART FAILURE; THROMBOCYTE ACTIVATION; THROMBOSIS; VON WILLEBRAND DISEASE; ADVERSE DEVICE EFFECT; BLOOD; HEART ASSIST DEVICE; HEART FAILURE; METABOLISM; PHYSIOLOGY; POSTOPERATIVE COMPLICATION;

BLOOD COAGULATION; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; POSTOPERATIVE COMPLICATIONS; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 85020066763     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2017.05.008     Document Type: Article

References (70)

1. Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 34 (2015), 1495–1504.
2. Miller, L.W., Pagani, F.D., Russell, S.D., et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 357 (2007), 885–896.
3. Aaronson, K.D., Slaughter, M.S., Miller, L.W., et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 125 (2012), 3191–3200.
4. Shah, P., Mehta, V.M., Cowger, J.A., et al. Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant 33 (2014), 102–104.
5. Stern, D.R., Kazam, J., Edwards, P., et al. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg 25 (2010), 352–356.
6. Stulak, J.M., Lee, D., Haft, J.W., et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 33 (2014), 60–64.
7. Rogers, J.G., Pagani, F.D., Tatooles, A.J., et al. intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med 376 (2017), 451–460.
8. Feldman, D., Pamboukian, S.V., Teuteberg, J.J., et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 32 (2013), 157–187.
9. Linneweber, J., Dohmen, P.M., Kertzscher, U., et al. The effect of surface roughness on activation of the coagulation system and platelet adhesion in rotary blood pumps. Artif Organs 31 (2007), 345–351.
10. Fraser, K.H., Zhang, T., Taskin, M.E., et al. A quantitative comparison of mechanical blood damage parameters in rotary ventricular assist devices: shear stress, exposure time and hemolysis index. J Biomech Eng, 134, 2012, 081002.
11. Prasad, S.M., Robertson, J.O., Itoh, A., et al. Histologic analysis of clots in explanted axial continuous-flow left ventricular assist devices. J Heart Lung Transplant 34 (2015), 616–618.
12. Sin, D.C., Kei, H.L., Miao, X., Surface coatings for ventricular assist devices. Exp Rev Med Dev 6 (2009), 51–60.
13. Mikhalovska, L.I., Santin, M., Denyer, S.P., et al. Fibrinogen adsorption and platelet adhesion to metal and carbon coatings. Thromb Haemost 92 (2004), 1032–1039.
14. Tsai, W.B., Grunkemeier, J.M., McFarland, C.D., et al. Platelet adhesion to polystyrene-based surfaces preadsorbed with plasmas selectively depleted in fibrinogen, fibronectin, vitronectin, or von Willebrand׳s factor. J Biomed Mater Res 60 (2002), 348–359.
15. Kawahito, K., Mohara, J., Misawa, Y., et al. Platelet damage caused by the centrifugal pump: in vitro evaluation by measuring the release of alpha-granule packing proteins. Artif Organs 21 (1997), 1105–1109.
16. Tamari, Y., Aledort, L., Puszkin, E., et al. Functional changes in platelets during extracorporeal circulation. Ann Thorac Surg 19 (1975), 639–647.
17. Diehl, P., Aleker, M., Helbing, T., et al. Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation. Interact Cardiovasc Thorac Surg 11 (2010), 133–137.
18. Nascimbene, A., Hernandez, R., George, J.K., et al. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transplant 33 (2014), 470–477.
19. Slaughter, M.S., Naka, Y., John, R., et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant 29 (2010), 616–624.
20. Netuka, I., Sood, P., Pya, Y., et al. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. J Am Coll Cardiol 66 (2015), 2579–2589.
21. Geisen, U., Heilmann, C., Beyersdorf, F., et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 33 (2008), 679–684.
22. Meyer, A.L., Malehsa, D., Budde, U., et al. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2 (2014), 141–145.
23. Siedlecki, C.A., Lestini, B.J., Kottke-Marchant, K.K., et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 88 (1996), 2939–2950.
24. Dassanayaka, S., Slaughter, M.S., Bartoli, C.R., Mechanistic pathway(s) of acquired von Willebrand syndrome with a continuous-flow ventricular assist device: in vitro findings. ASAIO J 59 (2013), 123–129.
25. John, R., Lee, S., The biological basis of thrombosis and bleeding in patients with ventricular assist devices. J Cardiovasc Transl Res 2 (2009), 63–70.
26. Alevriadou, B.R., Moake, J.L., Turner, N.A., et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 81 (1993), 1263–1276.
27. Klovaite, J., Gustafsson, F., Mortensen, S.A., et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 53 (2009), 2162–2167.
28. Meyer, A.L., Malehsa, D., Bara, C., et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 3 (2010), 675–681.
29. Jilma-Stohlawetz, P., Quehenberger, P., Schima, H., et al. Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent. Thromb Res 137 (2016), 196–201.
30. Demirozu, Z.T., Radovancevic, R., Hochman, L.F., et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 30 (2011), 849–853.
31. Hasin, T., Marmor, Y., Kremers, W., et al. Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol 61 (2013), 153–163.
32. Letsou, G.V., Shah, N., Gregoric, I.D., et al. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 24 (2005), 105–109.
33. Suarez, J., Patel, C.B., Felker, G.M., et al. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail 4 (2011), 779–784.
34. Frazier, O.H., Unforeseen consequences of therapy with continuous-flow pumps. Circ Heart Fail 3 (2010), 647–649.
35. Wever-Pinzon, O., Selzman, C.H., Drakos, S.G., et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 6 (2013), 517–526.
36. Muthiah, K., Connor, D., Ly, K., et al. Longitudinal changes in hemostatic parameters and reduced pulsatility contribute to non-surgical bleeding in patients with centrifugal continuous-flow left ventricular assist devices. J Heart Lung Transplant 35 (2016), 743–751.
37. Maltais, S., Kilic, A., Nathan, S., et al. PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: the PREVENT multi-center study. J Heart Lung Transplant 36 (2017), 1–12.
38. Draper, K., Kale, P., Martin, B., et al. Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 34 (2015), 132–134.
39. Aggarwal, A., Pant, R., Kumar, S., et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg 93 (2012), 1534–1540.
40. Tabit, C.E., Chen, P., Kim, G.H., et al. Elevated angiopoietin-2 level in patients with continuous-flow left ventricular assist devices leads to altered angiogenesis and is associated with higher nonsurgical bleeding. Circulation 134 (2016), 141–152.
41. Montezano, A.C., Touyz, R.M., Reactive oxygen species and endothelial function—role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin Pharmacol Toxicol 110 (2012), 87–94.
42. Nielsen, V.G., Sobieski, M.A. 2nd, Slaughter, M.S., Left ventricular assist device-associated carbon monoxide and iron-enhanced hypercoagulation: impact of concurrent disease. ASAIO J 61 (2015), 417–423.
43. Nielsen, V.G., Pretorius, E., Iron and carbon monoxide enhance coagulation and attenuate fibrinolysis by different mechanisms. Blood Coagul Fibrinolysis 25 (2014), 695–702.
44. Arkebauer, M.R., Kanaparthy, S.S., Malayaman, S.N., et al. Carbon monoxide and nitric oxide modulate alpha(2)-antiplasmin and plasmin activity: role of heme. Blood Coagul Fibrinolysis 22 (2011), 712–719.
45. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). http://www.intermacs.org/. Accessed February 8, 2013.
46. Cowger, J.A., Romano, M.A., Shah, P., et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant 33 (2014), 35–43.
47. Starling, R.C., Moazami, N., Silvestry, S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370 (2014), 33–40.
48. Kirklin, J.K., Naftel, D.C., Kormos, R.L., et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 33 (2014), 12–22.
49. Shah, P, Birk, S., Maltais, S., et al. Left ventricular assist device outcomes based on flow configuration and pre-operative left ventricular dimension: an Interagency Registry for Mechanically Assisted Circulatory Support analysis. J Heart Lung Transplant 36 (2017), 640–649.
50. Najjar, S.S., Slaughter, M.S., Pagani, F.D., et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 33 (2014), 23–34.
51. Stulak, J.M., Davis, M.E., Haglund, N., et al. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg 151 (2016), 177–189.
52. Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS Registry. J Heart Lung Transplant 34 (2015), 1515–1526.
53. Stulak, J.M., Dunlay, S.M., Sharma, S., et al. Treatment of device thrombus in the HeartWare HVAD: Success and outcomes depend significantly on the initial treatment strategy. J Heart Lung Transplant 34 (2015), 1535–1541.
54. Scandroglio, A.M., Kaufmann, F., Pieri, M., et al. Diagnosis and treatment algorithm for blood flow obstructions in patients with left ventricular assist device. J Am Coll Cardiol 67 (2016), 2758–2768.
55. Boyle, A.J., Russell, S.D., Teuteberg, J.J., et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 28 (2009), 881–887.
56. Saeed, O., Shah, A., Kargoli, F., et al. Antiplatelet therapy and adverse hematologic events during Heart Mate II support. Circ Heart Fail, 9, 2016, e002296.
57. Netuka, I., Litzler, P.Y., Berchtold-Herz, M., et al. Minimal adverse events in HeartMate II patients with no antiplatelet therapy: preliminary results from the european TRACE study. J Heart Lung Transplant, 33(suppl), 2014, S11.
58. Clinicaltrials.gov. Prevention of non-surgical bleeding by management of HeartMate II patients without antiplatelet therapy (PREVENT II). https://clinicaltrials.gov/ct2/show/NCT02836652?term=NCT02836652&rank=1/. Accessed May 3, 2017.
59. Farrar, D.J., Bourque, K., Dague, C.P., et al. Design features, developmental status, and experimental results with the HeartMate III centrifugal left ventricular assist system with a magnetically levitated rotor. ASAIO J 53 (2007), 310–315.
60. Mehra, M.R., Naka, Y., Uriel, N., et al. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med 376 (2017), 440–450.
61. Netuka, I., Kvasnicka, T., Kvasnicka, J., et al. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. J Heart Lung Transplant 35 (2016), 860–867.
62. Pollari, F., Fischlein, T., Fittkau, M., et al. Anticoagulation with apixaban in a patient with a left ventricular assist device and gastrointestinal bleeding: a viable alternative to warfarin?. J Thorac Cardiovasc Surg 151 (2016), e79–e81.
63. Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (2013), 1206–1214.
64. Pieri, M., Agracheva, N., Di Prima, A.L., et al. Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices. Artif Organs 38 (2014), 342–346.
65. Pappalardo, F., Scandroglio, A.M., Potapov, E., et al. Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol 78 (2012), 330–335.
66. Fried, J., Levin, A.P., Mody, K.M., et al. Prior hematologic conditions carry a high morbidity and mortality in patients supported with continuous-flow left ventricular assist devices. J Heart Lung Transplant 33 (2014), 1119–1125.
67. Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
68. Floroff, C.K., Rieger, K.L., Veasey, T.M., et al. assessment of bleeding and thrombosis based on aspirin responsiveness after continuous-flow left ventricular assist device placement. ASAIO J, 2017.
69. Slepian, M.J., Sheriff, J., Hutchinson, M., et al. Shear-mediated platelet activation in the free flow: perspectives on the emerging spectrum of cell mechanobiological mechanisms mediating cardiovascular implant thrombosis. J Biomech 50 (2017), 20–25.
70. Birschmann, I., Dittrich, M., Eller, T., et al. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant 33 (2014), 80–87.